Robert Dillman
Seminars
• Strategically pursuing designations like Breakthrough Therapy or ISTs to validate early clinical signals, gain FDA partnership, and build external confidence in your platform’s viability
• Using regulatory milestones to strengthen investor narratives by showcasing derisked development timelines, alignment with FDA expectations, and faster routes to market
• Designing early trials with regulatory engagement in mind, including endpoint justification, biomarker integration, and data packages that support designation eligibility and smooth progression to pivotal trial
• Coordinating tumor biopsy with standard-of-care procedures to streamline sample collection and preserve cell viability
• Using biologically driven antigen selection and dendritic cell delivery to bypass lengthy genomic prediction and adjuvant formulation
• Reducing turnaround time to under 3 weeks and costs below $10K to improve patient access
